Statin use is associated with reduced risk of haematological malignancies: Evidence from a meta-analysis

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Yi, Xiao ^a   Jia, Wei ^a   Jin, Yin ^a   Zhen, Shang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG USE; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; LEUKEMIA; LYMPHOMA; NONHODGKIN LYMPHOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

HEMATOLOGIC NEOPLASMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84900330115     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087019     Document Type: Article

References (46)

1. Rodriguez-Abreu D, Bordoni A, Zucca E (2007) Epidemiology of hematological malignancies. Ann Oncol 18 Suppl 1: i3-i8. (Pubitemid 46344633)
2. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
3. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380: 581-590.
4. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, et al. (2008) Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 52: 1769-1781.
5. Bansal D, Undela K, D'Cruz S, Schifano F (2012) Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One 7: e46691.
6. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W (2013) Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144: 323-332.
7. Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367: 1792-1802.
8. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, et al. (2002) Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia 4: 337-346. (Pubitemid 34755844)
9. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, et al. (2002) 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122: 308-317. (Pubitemid 34116983)
10. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, et al. (2002) 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 91: 143-150. (Pubitemid 34827225)
11. Weis M, Heeschen C, Glassford AJ, Cooke JP (2002) Statins have biphasic effects on angiogenesis. Circulation 105: 739-745. (Pubitemid 34157379)
12. Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16: 508-519. (Pubitemid 34460459)
13. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012. (Pubitemid 30214957)
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560. (Pubitemid 37088507)
15. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. (Pubitemid 17189972)
16. Woolf B (1955) On estimating the relation between blood group and disease. Ann Hum Genet 19: 251-253.
17. Higgins JP, Thompson SG (2004) Controlling the risk of spurious findings from meta-regression. Stat Med 23: 1663-1682. (Pubitemid 38765338)
18. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
19. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. (Pubitemid 27387172)
20. Vinogradova Y, Coupland C, Hippisley-Cox J (2011) Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer 11: 409.
21. Chao C, Xu L, Abrams DI, Towner WJ, Horberg MA, et al. (2011) HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. AIDS 25: 1771-1777.
22. Coogan PF, Rosenberg L, Strom BL (2007) Statin use and the risk of 10 cancers. Epidemiology 18: 213-219.
23. Landgren O, Zhang Y, Zahm SH, Inskip P, Zheng T, et al. (2006) Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women. Cancer Epidemiol Biomarkers Prev 15: 2342-2347. (Pubitemid 46048288)
24. Iwata H, Matsuo K, Hara S, Takeuchi K, Aoyama T, et al. (2006) Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies. Cancer Sci 97: 133-138. (Pubitemid 43379481)
25. Fortuny J, de Sanjose S, Becker N, Maynadie M, Cocco PL, et al. (2006) Statin use and risk of lymphoid neoplasms: results from the European Case-Control Study EPILYMPH. Cancer Epidemiol Biomarkers Prev 15: 921-925. (Pubitemid 43823519)
26. Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, et al. (2004) Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 15: 419-428. (Pubitemid 38988028)
27. Blais L, Desgagne A, LeLorier J (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160: 2363-2368.
28. Traversa G, Menniti-Ippolito F, Da Cas R, Mele A, Pulsoni A, et al. (1998) Drug use and acute leukemia. Pharmacoepidemiol Drug Saf 7: 113-123. (Pubitemid 28252985)
29. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ (2004) The risk of cancer in users of statins. J Clin Oncol 22: 2388-2394. (Pubitemid 41115396)
30. Lutski M, Shalev V, Porath A, Chodick G (2012) Continuation with statin therapy and the risk of primary cancer: a population-based study. Prev Chronic Dis 9: E137.
31. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM (2011) Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 71: 1763-1771.
32. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, et al. (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17: 27-36. (Pubitemid 351166615)
33. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, et al. (2005) Cancer risk among statin users: a population-based cohort study. Int J Cancer 114: 643-647. (Pubitemid 40349625)
34. Bulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, et al. (2011) Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 378: 2013-2020.
35. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, et al. (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364: 771-777. (Pubitemid 39165096)
36. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, et al. (2003) Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361: 2024-2031. (Pubitemid 36695044)
37. LIPID Study Group (2002) Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 359: 1379-1387.
38. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, et al. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615-1622. (Pubitemid 28248586)
39. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009. (Pubitemid 26338729)
40. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, et al. (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7: 687-692. (Pubitemid 32588024)
41. Kwak B, Mulhaupt F, Myit S, Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399-1402. (Pubitemid 32001026)
42. Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, et al. (2000) Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 80: 1095-1100. (Pubitemid 30483228)
43. Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW (2013) JAK2- V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth. Br J Haematol 160: 177-187.
44. Gronich N, Drucker L, Shapiro H, Radnay J, Yarkoni S, et al. (2004) Simvastatin induces death of multiple myeloma cell lines. J Investig Med 52: 335-344. (Pubitemid 39447365)
45. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, et al. (2001) Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 15: 1398-1407. (Pubitemid 32785309)
46. Matar P, Rozados VR, Binda MM, Roggero EA, Bonfil RD, et al. (1999) Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma. Clin Exp Metastasis 17: 19-25. (Pubitemid 29284560)